动态监测D-二聚体在肿瘤患者导管相关性血栓的临床意义

doi:10.11904/j.issn.1002-3070.2019.05.008

Abstract

Abstract: Objective The objective of this study was to investigate the correlation between D-dimer levels and the occurrence of catheter related thrombosis(CRT)in tumor patients.Methods A prospective study was performed on 100 cancer patients with deep venous catheterization.The plasma D-dimer and intravenous Doppler ultrasonography were used to observe the incidence,time and thrombus type of CRT.Results The incidence of CRT was 12.6%,and asymptomatic thrombosis accounted for 83.3%.58.3% of the thrombosis occurred within 2 weeks after catheterization,and 91.7% occurred within 4 weeks after catheterization.After 2 weeks of catheterization,the level of D-dimer in the thrombosis group was significantly higher than that in the non-thrombosis group(P=0.013).Conclusion Most of the CRT in tumor patients is formed within 4 weeks after deep venous catheterization.The proportion of asymptomatic thrombus is high,and dynamic monitoring of D-dimer may be helpful for early diagnosis.

Key words: D-dimer, Cancer, Catheter related thrombosis

CLC Number:

R730.6

YANG Min, XIE Junying, TAN Peizhao, WU Xiaoming, YU Lei. Clinical significance of dynamic monitoring of D-dimer in catheter related thrombosis of cancer patients[J]. Journal of Practical Oncology, 2019, 33(5): 425-430.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2019.05.008

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2019/V33/I5/425

References

1 Verso M,Agnelli G.Venous thromboembolism associated with long-term use of central venous catheters in cancer patients[J].J Clin Oncol,2003,21(19):3665-3675.
2 Lee AY,Levine MN,Butler G,et al.Incidence,risk factors,and outcomes of catheter-related thrombosis in adult patients with cancer[J].J Clin Oncol,2006,24(9):1404-1408.
3 Khorana AA,Francis CW,Culakova E,et al.Frequency,risk factors,and trends for venous thromboembolism among hospitalized cancer patients[J].Cancer,2007,110(10):2339-2346.
4 Murray J,Precious E,Alikhan R.Catheter-related thrombosis in cancer patients[J].Br J Haematol,2013,162(6):748-757.
5 Lee KW,Bang SM,Kim S,et al.The incidence,risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer[J].J Thromb Haemost,2010,8(3):540-547.
6 Lyman GH,Bohlke K,Falanga A,et al.Venous thromboembolism prophylaxis and treatment in patients with cancer:American Society of Clinical Oncology clinical practice guideline update[J].J Oncol Pract,2015,11(3):442-444.
7 Mandalà M,Falanga A,Roila F,et al.Management of venous thromboembolism(VTE)in cancer patients:ESMO clinical practice guidelines[J].Ann Oncol,2011,22(Suppl 6):85-92.
8 Kearon C,Akl EA,Ornelas J,et al.Antithrombotic therapy for VTE disease:CHEST Guideline and Expert Panel Report[J].Chest,2016,149(2):315-352.
9 Farge D,Bounameaux H,Brenner B,et al.International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer[J].Lancet Oncol,2016,17(10):452-466.
10 Riondino S,Ferroni P,Zanzotto FM,et al.Predicting VTE in cancer patients:candidate biomarkers and risk assessment models[J].Cancers(Basel),2019,11(1):95.
11 Debourdeau P,Espié M,Chevret S,et al.Incidence,risk factors,and outcomes of central venous catheter-related thromboembolism in breast cancer patients:the CAVECCAS study[J].Cancer Medicine,2017,6(11):2732-2744.
12 Nañez-Terreros H,Jaime-Perez JC,Muñoz-Espinoza LE,et al.D-dimer from central and peripheral blood samples in asymptomatic central venous catheter-related thrombosis in patients with cancer[J].Phlebology,2019,34(1):52-57.
13 Jansen FH,van der Straaten HM,Roest M,et al.Elevated levels of D-dimer and fragment 1+2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis[J].Haematologica,2005,90(4):499-504.
14 Ferroni P,Martini F,Portarena I,et al.Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients[J].Clin Lung Cancer,2012,13(6):482-487.
15 Kondo S,Sasaki M,Hosoi H,et al.Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma[J].Oncotarget,2018,9(24):16883-16890.
16 Park K,Ryoo BY,Ryu MH,et al.Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy:A prospective study[J].World J Gastrointest Oncol,2017,15;9(4):176-183.
17 Evans RS,Sharp JH,Linford LH,et al.Risk of symptomatic DVT associated with peripherally inserted central catheters[J].Chest,2010,138(4):803-810.
18 Di Nisio M,Lee AYY,Carrier M,et al.Diagnosis and treatment of incidental venous thromboembolism in cancer patients:Guidance from the SSC of the ISTH[J].J Thromb Haemost,2015,13(5):880-883.
19 Gary T,Belaj K,Steidl K,et al.Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients:impact on short-term survival[J].Br J Cancer,2012,107(8):1244-1248.
20 Font C,Farrús B,Vidal L,et al.Incidental versus symptomatic venous thrombosis in cancer:a prospective observational study of 340 consecutive patients[J].Ann Oncol,2011,22(9):2101-2106.
21 Bozkaya Y,Ozdemir N,Demirci NS,et al.Prognostic Effect of symptomatic and asymptomatic venous thromboembolism in patients with gastric cancer[J].Uluslararasi Hematoloji-Onkoloji Dergisi,2017,27(2):100-109.
22 Boddi M,Villa G,Chiostri M,et al.Incidence of ultrasound-detected asymptomatic long-term central vein catheter-related thrombosis and fibrin sheath in cancer patients[J].Eur J Haematol,2015,95(5):472-479.
23 Liu Y,Gao Y,Wei L,et al.Peripherally inserted central catheter thrombosis incidence and risk factors in cancer patients:a double-center prospective investigation[J].Ther Clin Risk Manag,2015,11:153-160.
24 Walshe LJ,Malak SF,Eagan J,et al.Complication rates among cancer patients with peripherally inserted central catheters[J].J Clin Oncol,2002,20(15):3276-3281.

[1]	LIU Siwei, CUI Yue, SUN Yuanyuan, HU Jing, ZHANG Wenrui, CAO Mengru. Effect of FOXD3 in lung cancer cells [J]. Journal of Practical Oncology, 2019, 33(5): 390-396.
[2]	ZHOU Yaoyao, CHEN Fengyun, TU Wenluo. Palmitate inhibits proliferation of cervical cancer Hela cells by promoting apoptosis [J]. Journal of Practical Oncology, 2019, 33(5): 402-406.
[3]	SONG Ling, FU Qiong. Astragalin inhibits hypoxia-induced proliferation and invasion of ovarian cancer cells by up-regulating PHD2 [J]. Journal of Practical Oncology, 2019, 33(5): 407-414.
[4]	ZHANG Yiwei, SHI Jing, LIU Yupeng, CAO Liming, HU Fulan, ZHAO Yashuang. Relationship between methylation of USP1 gene in peripheral blood and prognosis risk of colorectal cancer [J]. Journal of Practical Oncology, 2019, 33(5): 420-424.
[5]	SHI Manru, E Mingyan. Effect of delayed radiotherapy on the prognosis of patients with different molecular subtypes of breast cancer [J]. Journal of Practical Oncology, 2019, 33(5): 431-435.
[6]	XU Ting, YAN Feifei, ZHANG Chunhui, ZHANG Yanqiao. Analysis of clinical pathology and prognosis in patients with gastric cancer & bone metastasis [J]. Journal of Practical Oncology, 2019, 33(5): 436-441.
[7]	LI Lei, ZHANG Qingyuan. Clinical progress of anti-tumor vascular therapy for breast cancer [J]. Journal of Practical Oncology, 2019, 33(5): 461-465.
[8]	WANG Yu, QIAO Juanjuan, ZHANG Lei, LIU Siwei, YANG Shucai. The role of steroid hormones in breast cancer and its effect on cancer stem cells [J]. Journal of Practical Oncology, 2019, 33(5): 466-470.
[9]	LIU Eryu, YANG Hao, LIANG Guohua, ZHAO Yanfang, ZHAO Wenhui. Action for CDK4/6 inhibitors combined with mTOR inhibitors in breast cancer and its mechanism [J]. Journal of Practical Oncology, 2019, 33(5): 476-480.
[10]	AN Weiwei, TANG Yali, ZHAO Lianhua, YANG Yue, WANG Xinling. Polyphenylene-polysaccharide complex from pinus koraiensis extract induces apoptosis in human breast cancer MCF-7 cells [J]. Journal of Practical Oncology, 2019, 33(4): 289-293.
[11]	SHEN Li, WEI Juncheng. Effect of miRNA-409-3p expression on proliferation of cervical cancer cells and chemotherapy sensitivity of cisplatin [J]. Journal of Practical Oncology, 2019, 33(4): 300-304.
[12]	ZHANG Beilei, LI Yi, WU Tao, JIANG Feng, ZHAO Hongxi, LI Yanhong. Mechanism study of sanguinarine inhibiting tumor growth of ovarian cancer by apoptosis induction [J]. Journal of Practical Oncology, 2019, 33(4): 305-309.
[13]	LI Jing, WU Huazhen, LIU Jisuo. A study on the mechanism of mi-362 targeting six1 inhibiting proliferation and migration of cervical cancer cells [J]. Journal of Practical Oncology, 2019, 33(4): 310-316.
[14]	LIU Jintao, GAO Ling, ZHOU Huiui. Expression of MAGEA4 and EB1 proteins in lung cancer tissues and their correlation with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2019, 33(4): 334-339.
[15]	HU Lin, SHEN Jia. Growth differentiation factor 15 plays a role in predicting and monitoring the cardiotoxicity of epirubicin/cyclophosphamide-docetaxel-trastuzumab in the treatment of patients with HER-2 positive breast cancer [J]. Journal of Practical Oncology, 2019, 33(4): 340-345.

Clinical significance of dynamic monitoring of D-dimer in catheter related thrombosis of cancer patients

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments